Home › Compound Library › Ashwagandha (KSM-66)

Ashwagandha (KSM-66)

Adaptogenoral · inferred

Adaptogenic herb shown to reduce cortisol, improve stress resilience, and support thyroid function.

Projected serum levels — 600 mg, once daily

Ashwagandha (KSM-66)
Ashwagandha (KSM-66) modeled serum levels, 600 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Ashwagandha (KSM-66) modeled serum levels with a loading dose of 757 mg, then 600 mg once daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 600 mg once daily (oral).

Loading schedule: 757 mg on day 1, then 600 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 62.4 mg, trough ≈ 15.9 mg body load. Population-based estimate over 15 days for a 600 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Adaptogen
Route modeled
Oral
Model confidence
inferred
Half-life
10 h
Common dose
600 mg
Suggested maximum
1.8k mg/day
Reference dose range
300–1.8k mg (single dose)
Suggested cadence
once daily

Documented interactions

  • contraindicated
    Efavirenz (Sustiva) + Ashwagandha (KSM-66) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Ashwagandha (KSM-66) AUC by ~0.18x

  • contraindicated
    Rifampin + Ashwagandha (KSM-66) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Ashwagandha (KSM-66) AUC by ~0.18x

  • danger
    7-Hydroxymitragynine (7-OH) + Ashwagandha (KSM-66) CYP inhibition

    Ashwagandha (KSM-66) reversible_inhibitor of CYP3A4 predicted to change 7-Hydroxymitragynine (7-OH) AUC by ~2.20x

  • danger
    Alfuzosin (Uroxatral) + Ashwagandha (KSM-66) CYP inhibition

    Ashwagandha (KSM-66) reversible_inhibitor of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~3.33x

  • danger
    Alprazolam (Xanax) + Ashwagandha (KSM-66) CYP inhibition

    Ashwagandha (KSM-66) reversible_inhibitor of CYP3A4 predicted to change Alprazolam (Xanax) AUC by ~3.33x

  • danger
    Amlodipine (Norvasc) + Ashwagandha (KSM-66) CYP inhibition

    Ashwagandha (KSM-66) reversible_inhibitor of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~3.33x

Serum checks 273 modeled interaction pairings for ashwagandha (ksm-66) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults Chandrasekhar K et al. · Indian Journal of Psychological Medicine, 2012 DOI

    RCT found 300 mg twice daily of ashwagandha root extract significantly reduced stress and anxiety scores and lowered serum cortisol levels by 27.9% compared to placebo.

  2. Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving sexual function in women: a pilot study Dongre S et al. · BioMed Research International, 2015 DOI

    Pilot RCT showed ashwagandha supplementation significantly improved sexual function, arousal, and satisfaction in healthy women over 8 weeks.

  3. Effects of an aqueous extract of Withania somnifera on strength training: a randomized, double-blind, placebo-controlled trial Wankhede S et al. · Journal of the International Society of Sports Nutrition, 2015 DOI

    RCT found ashwagandha supplementation significantly increased muscle strength, muscle size, testosterone levels, and exercise recovery compared to placebo during resistance training.

3 published studies referenced in the app, each with a plain-language summary.